spdef expression vector Search Results


pcdna-spdef  (GenScript corporation)
90
GenScript corporation pcdna-spdef
( A ) Location of MUC5B Short (red, 766 bp) and Long (blue, 4532 bp) regions cloned into reporter constructs relative to the transcription start site (black arrow). ( B – F ) Mean (±SD) normalized luciferase activity of indicated Short (red; top) and Long (blue; bottom) MUC5B reporter constructs and respective empty vector (EV) control in A549 cells. ( B ) WT constructs under basal culture conditions ( n = 4/group, * P ≤ 0.05 versus EV via t test). ( C ) WT versus mutant constructs with binding site mutations for STAT3, ETS1, or both ( n = 4/group, * P ≤ 0.0001 versus WT via 1-way ANOVA with Bonferroni correction). ( D ) WT constructs cotransfected with <t>SPDEF</t> or STAT3 cDNA expression constructs or empty expression vector control (Ctrl; n = 4/group, * P ≤ 0.003 versus WT + Ctrl via 1-way ANOVA with Bonferroni correction). ( E and F ) WT constructs cotransfected with siRNA targeting SPDEF ( E ), STAT3 ( F ), or control (si Ctrl ; n = 4/group, * P ≤ 0.001 versus WT + si Ctrl via 1-way ANOVA with Bonferroni correction). ( G ) ChIP-qPCR analysis of mean (±SD) relative occupancy of SPDEF and IgG across the MUC5B –3 kb region in A549 cells ( n = 3 (IgG) or 4 (SPDEF) per group; * P ≤ 0.05 versus geometric mean of IgG occupancy at 3 negative control regions via t test. Schematic indicates locations of putative STAT/ETS1 binding sites and regions targeted by ChIP-qPCR primers. ( H ) Mean (±SD) normalized luciferase activity of WT and mutant MUC5B Short reporter constructs with G or variant T at the G/T transversion site, respectively ( n = 4/group). ( I ) qPCR analysis quantifying relative MUC5B expression in untransfected WT control (Ctrl-GG) and CRISPR-Cas9–edited WT (GG) and variant (TT) A549 clones ( n = 3/group). Data in each panel are representative of at least 3 independent experiments, except for I , which was performed in 2 independent clones for each genotype.
Pcdna Spdef, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spdef+expression+vector/pcdna+spdef/pmc07934873-143-0-11
Average 90 stars, based on 1 article reviews
pcdna-spdef - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
aav-m-spdef  (Vector Biolabs)
N/A
   Buy from Supplier
ad-h-spdef-shrna  (Vector Biolabs)
N/A
   Buy from Supplier
ad-m-spdef  (Vector Biolabs)
N/A
   Buy from Supplier
aav-h-spdef  (Vector Biolabs)
N/A
   Buy from Supplier
ad-m-spdef-shrna  (Vector Biolabs)
N/A
   Buy from Supplier
human spdef gene orf cdna clone expression plasmid  (Sino Biological)
N/A
Full length Clone DNA of Human SAM pointed domain containing ETS transcription factor
   Buy from Supplier
ad-h-spdef  (Vector Biolabs)
N/A
   Buy from Supplier

Image Search Results


( A ) Location of MUC5B Short (red, 766 bp) and Long (blue, 4532 bp) regions cloned into reporter constructs relative to the transcription start site (black arrow). ( B – F ) Mean (±SD) normalized luciferase activity of indicated Short (red; top) and Long (blue; bottom) MUC5B reporter constructs and respective empty vector (EV) control in A549 cells. ( B ) WT constructs under basal culture conditions ( n = 4/group, * P ≤ 0.05 versus EV via t test). ( C ) WT versus mutant constructs with binding site mutations for STAT3, ETS1, or both ( n = 4/group, * P ≤ 0.0001 versus WT via 1-way ANOVA with Bonferroni correction). ( D ) WT constructs cotransfected with SPDEF or STAT3 cDNA expression constructs or empty expression vector control (Ctrl; n = 4/group, * P ≤ 0.003 versus WT + Ctrl via 1-way ANOVA with Bonferroni correction). ( E and F ) WT constructs cotransfected with siRNA targeting SPDEF ( E ), STAT3 ( F ), or control (si Ctrl ; n = 4/group, * P ≤ 0.001 versus WT + si Ctrl via 1-way ANOVA with Bonferroni correction). ( G ) ChIP-qPCR analysis of mean (±SD) relative occupancy of SPDEF and IgG across the MUC5B –3 kb region in A549 cells ( n = 3 (IgG) or 4 (SPDEF) per group; * P ≤ 0.05 versus geometric mean of IgG occupancy at 3 negative control regions via t test. Schematic indicates locations of putative STAT/ETS1 binding sites and regions targeted by ChIP-qPCR primers. ( H ) Mean (±SD) normalized luciferase activity of WT and mutant MUC5B Short reporter constructs with G or variant T at the G/T transversion site, respectively ( n = 4/group). ( I ) qPCR analysis quantifying relative MUC5B expression in untransfected WT control (Ctrl-GG) and CRISPR-Cas9–edited WT (GG) and variant (TT) A549 clones ( n = 3/group). Data in each panel are representative of at least 3 independent experiments, except for I , which was performed in 2 independent clones for each genotype.

Journal: JCI Insight

Article Title: The MUC5B-associated variant rs35705950 resides within an enhancer subject to lineage- and disease-dependent epigenetic remodeling

doi: 10.1172/jci.insight.144294

Figure Lengend Snippet: ( A ) Location of MUC5B Short (red, 766 bp) and Long (blue, 4532 bp) regions cloned into reporter constructs relative to the transcription start site (black arrow). ( B – F ) Mean (±SD) normalized luciferase activity of indicated Short (red; top) and Long (blue; bottom) MUC5B reporter constructs and respective empty vector (EV) control in A549 cells. ( B ) WT constructs under basal culture conditions ( n = 4/group, * P ≤ 0.05 versus EV via t test). ( C ) WT versus mutant constructs with binding site mutations for STAT3, ETS1, or both ( n = 4/group, * P ≤ 0.0001 versus WT via 1-way ANOVA with Bonferroni correction). ( D ) WT constructs cotransfected with SPDEF or STAT3 cDNA expression constructs or empty expression vector control (Ctrl; n = 4/group, * P ≤ 0.003 versus WT + Ctrl via 1-way ANOVA with Bonferroni correction). ( E and F ) WT constructs cotransfected with siRNA targeting SPDEF ( E ), STAT3 ( F ), or control (si Ctrl ; n = 4/group, * P ≤ 0.001 versus WT + si Ctrl via 1-way ANOVA with Bonferroni correction). ( G ) ChIP-qPCR analysis of mean (±SD) relative occupancy of SPDEF and IgG across the MUC5B –3 kb region in A549 cells ( n = 3 (IgG) or 4 (SPDEF) per group; * P ≤ 0.05 versus geometric mean of IgG occupancy at 3 negative control regions via t test. Schematic indicates locations of putative STAT/ETS1 binding sites and regions targeted by ChIP-qPCR primers. ( H ) Mean (±SD) normalized luciferase activity of WT and mutant MUC5B Short reporter constructs with G or variant T at the G/T transversion site, respectively ( n = 4/group). ( I ) qPCR analysis quantifying relative MUC5B expression in untransfected WT control (Ctrl-GG) and CRISPR-Cas9–edited WT (GG) and variant (TT) A549 clones ( n = 3/group). Data in each panel are representative of at least 3 independent experiments, except for I , which was performed in 2 independent clones for each genotype.

Article Snippet: Expression constructs for SPDEF (pcDNA-SPDEF) and STAT3 (pcDNA-STAT3) were obtained from GenScript and Addgene, respectively; pcDNA3.1(+) empty vector control was purchased from Invitrogen.

Techniques: Clone Assay, Construct, Luciferase, Activity Assay, Plasmid Preparation, Control, Mutagenesis, Binding Assay, Expressing, ChIP-qPCR, Negative Control, Variant Assay, CRISPR